Clinicians can sometimes focus only on a patient’s medical needs, but listening to the patient’s own goals and priorities often reveals social drivers of health that must be addressed, said Renee Murray, associate clinical director of Care Management Initiatives at Camden Coalition.
Clinicians can sometimes focus only on a patient’s medical needs, but listening to the patient’s own goals and priorities often reveals social drivers of health that must be addressed, said Renee Murray, associate clinical director of Care Management Initiatives at Camden Coalition.
Transcript (slightly modified)
How does the Camden Coalition take into account the unmet social needs of patients and address those as part of care?
So, working with this 1% most medically and socially complex population, the medical complexities and the social complexities go hand in hand. It’s a marriage. When we are addressing needs with our patient population, we are asking them: you identify your priorities and goals. What is it that you want to focus on?
And that’s a different shift in healthcare as well, because so often we’re saying, this is what we recommend as the clinician, as the “expert,” right. I’m the expert, you’re the patient. I have the knowledge, I’m going to just transfer my knowledge to you in saying, this is how you should be tackling X, Y, and Z.
And we’re saying, you tell us what your goals and priorities are. And a lot of the time those goals and priorities are very socially driven. So we are embracing those social goals and priorities, and that’s what is allowing us to address putting the focus on what the patient is asking for, and most times it is something that is a social driver. As traditional medicine we’re just focusing on the clinical aspect, [but] we are very driven by what the patient is telling us and it’s often social.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More
2 Commerce Drive
Cranbury, NJ 08512